Rise in the incidences of acute lymphoblastic leukemia and increase in number of new product approvals drive the growth of the global acute lymphoblastic leukemia therapeutics market. On the other hand, patent expiry of blockbuster drugs and several side effects of the treatment restrain the growth to some extent. Nevertheless, growing number of clinical trials is …